Last reviewed · How we verify
Budesonide/formoterol Turbuhaler
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors.
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide/formoterol Turbuhaler |
|---|---|
| Also known as | Symbicort |
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Budesonide is an inhaled corticosteroid that suppresses inflammatory mediators and immune cell recruitment in the airways. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, providing sustained bronchodilation. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance and reliever therapy in asthma and COPD.
Approved indications
- Asthma maintenance and reliever therapy
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (PHASE3)
- Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) (NA)
- As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period (PHASE3)
- Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing. (PHASE3)
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |